Top Markets
Coin of the day
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
Classificação em ações #33297
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
Preço da ação
$0.4264
Última sincronização: 2022-09-14
Valor de mercado
$7.93M
Variação (1 dia)
-16.44%
Variação (1 ano)
0.00%
País
US
Negociar Caladrius Biosciences, Inc. (CLBS)

Categoria

Histórico de rendimento de dividendos para Caladrius Biosciences, Inc. (CLBS)
O rendimento de dividendos (TTM) da Caladrius Biosciences, Inc. (símbolo da ação: CLBS) em 2026 é: 0
Rendimento médio dos dividendos nos últimos 5 anos: 0.00%
Histórico de rendimento de dividendos para Caladrius Biosciences, Inc. (CLBS) de 2026 a 2026
Rendimento de dividendos no final de cada ano (TTM)
Ano Rendimento de Dividendos Alterar
Não há dados suficientes para as datas fornecidas.
Rendimentos de dividendos (TTM) para empresas semelhantes ou concorrentes
Empresa Rendimento de Dividendos País
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
0.48%
BE